Hanx Biopharmaceuticals executes HK$0.72 million share buyback, raises treasury stock to 109,800 shares

Bulletin Express04-14

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The transaction cost totalled HK$0.72 million.

Following the buyback, issued shares excluding treasury stock fell 0.017 % to 136.11 million, while treasury shares rose to 109,800. Total issued shares remained unchanged at 136.22 million.

The purchases were made under the repurchase mandate approved on 12 February 2026, which allows Hanx Biopharmaceuticals to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 109,800 shares, equivalent to 0.0806 % of the issued share base at the mandate date.

Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 10 May 2026. All repurchases were confirmed by the board as compliant with relevant regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176436451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176436451","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals executes HK$0.72 million share buyback, raises treasury stock to 109,800 shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The transaction cost totalled HK$0.72 million.</p>\n<p>Following the buyback, issued shares excluding treasury stock fell 0.017 % to 136.11 million, while treasury shares rose to 109,800. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The purchases were made under the repurchase mandate approved on 12 February 2026, which allows Hanx Biopharmaceuticals to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 109,800 shares, equivalent to 0.0806 % of the issued share base at the mandate date.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 10 May 2026. All repurchases were confirmed by the board as compliant with relevant regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals executes HK$0.72 million share buyback, raises treasury stock to 109,800 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals executes HK$0.72 million share buyback, raises treasury stock to 109,800 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-14 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The transaction cost totalled HK$0.72 million.</p>\n<p>Following the buyback, issued shares excluding treasury stock fell 0.017 % to 136.11 million, while treasury shares rose to 109,800. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The purchases were made under the repurchase mandate approved on 12 February 2026, which allows Hanx Biopharmaceuticals to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 109,800 shares, equivalent to 0.0806 % of the issued share base at the mandate date.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 10 May 2026. All repurchases were confirmed by the board as compliant with relevant regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1176436451","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176436451","pubTimestamp":1776177780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"Hanx Biopharmaceuticals执行72万港元股份回购，库存股增至10.98万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The transaction cost totalled HK$0.72 million.\nFollowing the buyback, issued shares excluding treasury stock fell 0.017 % to 136.11 million, while treasury shares rose to 109,800. Total issued shares remained unchanged at 136.22 million.\nThe purchases were made under the repurchase mandate approved on 12 February 2026, which allows Hanx Biopharmaceuticals to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 109,800 shares, equivalent to 0.0806 % of the issued share base at the mandate date.\nUnder Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 10 May 2026. All repurchases were confirmed by the board as compliant with relevant regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176436451","isCrawlerRequest":true}